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ABSTRACT
A five-year project, Access to Care was developed and implemented by the Sickle Cell Foundation of Georgia (SCFG) leveraging
community resources and partnerships to increase access and improve the quality of healthcare and healthcare coordination in an
adult sickle cell disease (SCD) population in underserved and rural areas of Georgia. The project is comprised of three phases:
(Phase 1) the Community Health Worker Program - to improve the health outcomes of individuals living with SCD through
healthcare coordination; (Phase 2) the CME-accredited Provider Training Program - to increase the knowledge of non-specialty
providers in Georgia to increase provider capacity and confidence to provide care and treatment for individuals with sickle cell
disease; and (3) Sickle Cell Clinic Days – specialty care provided by a hematologist in minimally resourced and underserved
areas including Augusta, Columbus, Macon and Savannah and counties. Eight hundred and sixty-nine (869) individuals in 75
Georgia counties have received care coordination services with 113 placed in medical homes. Three hundred and sixty-eight (368)
health care providers have participated in six face-to-face trainings and 30 have participated in two webinars. Partnerships include
local sickle cell associations and support groups; local health departments; hospitals/Emergency Departments; local medical
societies; local academic institutions; stakeholders; Georgia Department of Public Health; Global Blood Therapeutics; and
Morehouse School of Medicine. With 8,427 residents living with SCD, Georgia has the nation’s fourth largest SCD population in
the nation with the second highest SCD incidence among black and/or African American births in the nation. Evaluation measures
include process and output data monitoring, collection of observational data, i.e., participation and appointment tracking, and case
management recording utilizing case management software; pre-and post-questionnaires to measure changes in knowledge,
attitudes, skills covered in workshops and seminars.
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INTRODUCTION
The quality of life of individuals living with a chronic
condition is, in part, impacted by their access to appropriate
health care. Access to care is also one component of
preventing or delaying complications, improving function,
delaying
pain,
and
managing
disease
(https://www.healthypeople.gov/2020/). The Sickle Cell
Foundation of Georgia’s (SCFG) Access to Care Project is
designed to increase access, quality, and the level of
healthcare coordination for individuals living with sickle
cell disease (SCD) in the state of Georgia; diversify and
enrich Georgia’s talent pool of primary care and family
physicians
with
continuing
medical
education
(CME)-accredited training on the treatment of SCD; and
increase access to specialty (clinical) services for adult
out-of-care individuals living with SCD in rural and
underserved areas of Georgia.

oxygen transport molecule, hemoglobin, (Pauling, et. al.,
1941) wherein the amino acid glutamate is replaced by
valine. This amino acid substitution causes a distortion in
the shape of red blood cells from the normal biconcave disk
shape, producing rigid, sticky, sickle-shaped cells. These
sickle cells obstruct small blood vessels and capillaries
disrupting the flow of oxygen to body tissues. The
obstruction in the flow of blood coupled with oxygen
deprivation to tissues cause severe and debilitating pain,
known a vaso-occlusive episode (commonly referred to as
sickle cell or pain crises). The episodes are part of a genetic
pleiotropic effect that may impact every organ in the body,
causing multiple medical complications (Ilesanmi, 2013).
SCD is a complex, chronic illness affecting approximately
100,000 Americans. In the United States (U.S.) the disorder
is most prevalent among individuals of African descent,
followed by individuals of Hispanic, Middle Eastern, and
Indian descent.

Sickle cell disease (SCD) is a genetic blood disorder caused
by a defect in protein structure – an aberration in the red cell

Despite being the first identified molecular disorder (in
1910 and 1949), (Pauling, et. al., 1941) the progress in the

care, management, and survival of people with SCD has
lagged significantly. Advances in SCD treatment have been
limited compared with later discovered molecular disorders,
such as cystic fibrosis (CF)where more treatments have
been developed to benefit patient populations. Though both
are devastating conditions with shortened life expectancies,
between 2009 and 2013, there were nearly twice as many
publications and slightly more clinical trials for CF than
SCD. Between 2010 and 2013, five new drugs were
developed for CF and none were developed for SCD
(Strouse, et. al., 2013).
Before the 1970s, most children with SCD in the U.S. died
before adolescence. Advances in treatment and the
establishment of comprehensive, highly specialized
pediatric centers decreased the mortality rate for children
with SCD by 3 percent each year in a study from 1979 to
2005 (Lanzkron, 2013). The collective scientific and
medical focus was on preventing children from dying.
However, there was little foresight regarding what happens
to these children when they become adults. The Lanzkron
(2013) study found that mortality rates for adults with SCD
increased by 1 percent during the same period with a life
expectancy reduced by approximately 30 years. Currently,
the only available cure is limited to bone marrow
transplantation and the promise of gene therapies currently
in clinical trials. Options available to only a very small
segment of the SCD population. Of the 762 drugs approved
by the U.S. Food and Drug Administration for orphan
diseases (population <200,000) between 1983 and 2018,
only two were for SCD (U.S. Food, 2019 & U.S. Food,
2019). Two additional drugs were introduced in 2019.
Medical complications and frequent hospitalizations often
disrupt the lives of individuals living with SCD, interrupting
schooling and compromising their ability to maintain steady
employment. This leaves some segments of adults with SCD
uninsured and underinsured making most SCD centers
money-losing cost centers. As a result, the number of
hematologists, core providers for individuals with SCD,
who care for patients with nonmalignant conditions is
distressingly low (Marshall, 2018). The lack of health care
providers with comprehensive knowledge to care for
individuals with SCD makes it difficult for individuals to
receive the standard of care necessary to improve health
outcomes and reduce mortality.
Georgia is the 9th most populous state in the U.S. (U.S.
Census Bureau, 2020) with the fourth largest population of
individuals with SCD (8,427) nation-wide (Hassel, 2010).
Of the 159 counties in the state, 148 (93%) are designated as
medically underserved and 108 counties (68%) are rural
(population=<35,000) (Georgia State Office of Rural
Health, 2011). The state has two comprehensive SCD
centers for adults located in North (Metropolitan Atlanta)
and East Central (Augusta) Georgia, with hematologists
centralized in those areas. Non-specialty health care
providers throughout the state reported reluctance to care for

individuals with SCD because of lack of knowledge and
negative perceptions of individuals with SCD; and would
prefer to refer them to specialists (Georgia Health Policy
Center, 2014). Consequently, individuals with sickle cell
disease face a minimum two-hour drive for specialty care
often creating a higher reliance on emergency departments
at significantly higher costs and decreased quality of care.
Engaging non-hematologists as care providers for
individuals with SCD is vital to addressing the provider
deficit. Training by skilled SCD providers could greatly
enhance the knowledge and confidence of primary care
providers, especially if training is coupled with access to a
hematologist. Leveraging available capacity within existing
medical center infrastructure can be an effective mechanism
for creating care programs for individuals with SCD at a
lower cost. Federally Qualified Health Centers (FQHC)
could be a key support because of their focus on disease
prevention and long-term management of chronic conditions
(Access to Care Summit proceedings, 2019).
Increasing access to care requires patient support.
Individuals with SCD face several challenges, including
navigating a maze of providers, scheduling appointments,
and managing a large array of medication and medical
regimes. Additionally, social determinants of health –
inadequate housing, food insecurity, understanding of
disease self-management, etc. can impact health seeking
behaviors and undermine health outcomes. Community
Health Workers (CHWs) are trusted, knowledgeable
frontline health personnel who typically come from the
communities they serve. CHWs bridge cultural and
linguistic barriers, expand access to coverage and care, and
improve health outcomes. As critical links between their
communities and the health care system, CHWs reduce
health disparities; boost health care quality, cultural
competence and affordability; and empower individuals and
communities for better health (American Public Health
Association, 2009). In a study conducted by Overholser, et.
al. (2014) utilizing CHWs to increase access to care by
individuals with sickle cell disease, 62% of patients
identified a primary care provider and attended a first
appointment. CHWs help bridge to medical services to
improve
healthcare
engagement,
self-management,
treatment plan adherence, and health outcomes (Hsu, 2016).
Such patient assistance programs are associated with fewer
missed appointments, which correlate with costly
hospitalizations and readmissions.
METHODS
Phase I Community Health Workers
SCFG secured Health Resources and Services
Administration (HRSA) Sickle Cell Disease Newborn
Screening funding in 2015 for two years (2015-2016)
through the Sickle Cell Disease Association of America
(SCDAA) to start a CHW Program to improve the health
outcomes of individuals living with SCD. During the first

year of funding (2015), SCFG developed a five-year plan
presented to the Georgia State Legislature to increase access
to care with incremental funding. The five-year plan
proposed a public-private partnership between the state and
community organizations to improve the quality of life and
SCD care access in the state of Georgia. Registry and
Surveillance System for Hemoglobinopathies (RuSH) data
were used to target areas of the state with high rates of SCD
and community potential partners were identified:
● Augusta – East Georgia
● Columbus – Midwest Georgia
● Macon – Central Georgia
● Savannah – Southeast Georgia
During this first two-year period of the project, CHWs were
located in Metropolitan Atlanta and in Columbus in
partnership with the local sickle cell association. SCFG
engaged the local community partner to generate strategies
that would be implemented in the Columbus area to improve
health outcomes of individuals living with SCD. The local
partner identified the needs of individuals in Columbus
living with SCD, their health seeking behaviors, and
available community resources. Included in the planning
process was the identification of potential candidates to
serve as a CHW for the Columbus area. The local partner
provided office space for the CHW and collaborated with
the CHW to identify individuals with SCD in need of care
coordination services.
In 2017, SCFG expanded the deployment of CHWs to
Augusta and Macon; and initiated planning for expansion to
Savannah. SCFG partnered with the sickle cell support
group in Macon to provide office space. In each of the
cities, CHWs established partnerships with the local health
departments, FQHCs, hospitals, clinics, and community
organizations. Community partners served as a source of
referrals for the CHW and a resource for primary care and
other community services. CHWs provided appointment
assistance, resource coordination, linkages to primary care,
and follow-up. In Macon, the CHW partnered with the
telemedicine hematology team to ensure individuals kept
their appointments and were linked to a primary care
provider.
In 2018, a CHW was hired to service Savannah and the
surrounding area. SCFG worked closely with the local SCD
association to establish a relationship with one of the
FQHCs in Savannah. The partnership with the FQHC
included office space for the CHW and clinical space for a
visiting hematologist. Through efforts of the CHW, the
FQHC serves as a medical home for un-insured and
under-insured individuals with SCD in Savannah. The CHW
quickly established a partnership with the Memorial Health
Children’s Hospital of Savannah and provides support to the
hospital’s transition program, established in 2019.
Phase II: Provider Training

In 2018, SCFG initiated provider training in areas of the
state with no hematologist. A curriculum was developed to
include caring for persons with SCD in non-specialty
settings; overview of SCD; pain management; emerging
trends; protocols for management in emergency settings;
and care coordination using CHWs. The 2014 National
Heart, Lung, and Blood Institute’s “Evidence-Based
Management of Sickle Cell Disease” (U.S. Department of
Health and Human Services, 2014) is used as a basis for
clinical instruction. The training is led by an expert
hematologist and a family medicine physician with
extensive experience with SCD treatment in family
medicine and emergency department settings. In partnership
with Morehouse School of Medicine, providers earn up to
four CME credits for the four-hour course. Providers are
encouraged to participate in the Extension for Community
Health Care Outcomes (ECHO) sponsored by Atrium
Health for additional training and to enroll in the U.S.
Department of Health and Human Services, Office of
Minority Health Sickle Cell Disease Training and
Mentoring Program (STAMP) to gain access to
consultations with sickle cell experts.
A toolkit (see Appendix for list of contents) was developed
and is disseminated during the training to include the
American Society of Hematology clinical pocket guides of
evidence-based practices, emergency department protocols,
and other physician-focused materials. Training participants
have included family medicine providers, nurse
practitioners, pediatricians, internists, nurses, OB/GYN
providers, emergency department physicians, physician
assistants, medical assistants, and medical students. SCFG
collaborated with local stakeholders to plan, coordinate, and
deliver training – community based organizations, health
departments, academic institutions, hospitals, FQHCs, and
local SCD organizations. Local partners identify facilities,
assist with marketing; and in some instances, participate as
presenters.
Phase III: Sickle Cell Clinic Days
In 2019, SCFG established Memoranda of Understanding
(MOU) and Business Associates Agreements with
community health centers, health departments, and FQHCs
in Columbus, Macon, and Augusta to host “Sickle Cell
Disease Clinic Days” at their facilities. SCFG Medical
Director and Operations Manager collaborated with the
Clinical Directors to establish protocols to be used at each
facility – appointment setting; facility enrollment (at
FQHCs); lab work; facility liaison; medical record sharing;
forms; intake; prescriptions; etc.
The first clinic day was held at a FQHC in Savannah
followed by clinic days at a FQHC and a community health
center in Columbus. In Savannah, the CHW makes
appointments and facilitates FQHC enrollment for labs,
prescriptions, and primary care. The facility provides a
nurse liaison to expedite any lab work needed. In Columbus,
both facilities have patients with SCD and appointments are

managed by facility staff. New patients are also managed by
facility staff. The hematologist makes monthly visits to the
facilities seeing no more than 15 patients per visit.
RESULTS
Since inception, 869 individuals in 75 Georgia counties
have received care coordination services with 113 placed in
medical homes (primary care). The Social Functioning and
Emotional Distress Scales of the Adult Sickle Cell Quality
of Life Measurement System (ASCQ-Me short forms) were
used to measure changes in the two constructs of individuals
receiving CHW services in Metropolitan Atlanta, July
through December 2019. Seventy-two percent (72.4%) of
individuals receiving services reported improvement in
social functioning (less difficult to engage in social
functions, less difficult to get out and do things they enjoy).
Respondents reported that after receiving CHW services,
they:
● relied less on others to take care of them
● were slowed down less by their health
● found it less difficult for them to do the things they
like
● were prevented from going out less often
● found it less difficult to do things with their friends
Sixty-eight percent (68.7%) reported improvement in
emotional distress (worried less about getting sick and
needing to go to the hospital). Respondents reported that
after services, they experienced:
● reduced feelings of complete hopelessness because
of their health
● reduced feeling of loneliness
● less depressed feelings about their health problems
● less worry about getting sick
● less worry about needing to go to the hospital
Three hundred and sixty-eight health care providers have
participated in six face-to-face trainings and 30 have
participated in two webinars.
● 91% reported increases in disease knowledge
● 87% reported increases in knowledge of disease
management
and
treatment,
and
better
understanding of patient experience
● 77% reported improved comfort levels treating
individuals with SCD
● 89% reported a desire for a follow-up support
mechanism
A total of 40 patients have been seen at the FQHCs and
community health center in Savannah and Columbus.
Patients have reported high levels of satisfaction with the
services received and the number of patients is slowly
increasing. A small number of patients from the southern
part of the state travel an hour or more to their Sickle Cell
Clinic Day appointment in Savannah. However, most
identify not having to drive long distances to see a
hematologist as the most significant advantage of the Sickle
Cell Clinic Days.

DISCUSSION
This project builds on leveraging existing resources, thus
taking the time to understand the local landscape is critical
to the successful implementation of this kind of project.
Local stakeholder input and ownership requires time and
patience. Each location has its own politics, culture, and
motivations for project involvement and each presents
lessons learned to be applied to the next location. For
example, the patient profile in Columbus differs greatly
from the patient profile in Savannah. Columbus has no
hematologists, adult or pediatric. Over the last year, a
monthly pediatric SCD clinic has operated out of a local
pediatrician’s office. Adult patients in Columbus are diverse
in age, income, and educational levels and have had to drive
two hours to see a hematologist. In many instances, they
have been in care though not as regularly because of the
need to travel. Savannah has a very limited number of
hematologists. Most of the Savannah Sickle Cell Clinic
Days patients tend to be young adults – college students or
recent graduates with limited income and no insurance.
Many of the Savannah patients had not seen a hematologist
in over a year and had been receiving care in emergency
departments and urgent care centers. Some are emerging
adults making their first adult appointment before leaving
pediatric care. A small number are established adults from
the more southern part of the state with no hematologists.
In Columbus we discovered variability in capacity and
infrastructure of community health centers that we had not
expected. During a clinic day, we found that one of the
centers did not have a laboratory on site and used a third
party. The lesson learned is to collect comprehensive
capacity information from potential partners to determine
the most efficient and practical way to provide hematology
services in that location. It is also necessary to ascertain if
the location is suitable for a one-day clinic.
The CHW program has served as the foundation for the
overall project. Not only do they serve as liaisons between
the individuals living with SCD and medical and
community resources, because they are an established part
of the community, they serve as liaisons between local
stakeholders and other aspects of the project. They also play
an important role in getting individuals to their
appointments with both reminders and support, such as
arranging transportation. Within the FQHCs and community
health centers, relationships have been forged between the
visiting hematologist and the SCFG Medical Director
(family practice). Increasingly, FQHC providers are
reaching out to the SCFG clinical staff for consultations on
specific cases involving individuals with SCD they are
caring for.
SCFG is a non-clinical community based organization and
there was a learning curve in understanding how to actually
provide clinical services in these very different communities

and how the CHWs function. We grossly overestimated the
number of patients that the hematologist could see in a visit,
underestimated the amount of time needed for new patients,
and did not account for the time needed for both
stakeholders and patients to get acclimated to the program.
Because significant travel is involved for the hematologist,
establishing predictable, monthly schedules for the cities
saves on travel costs. A consideration to expand the reach of
adult hematology services is to ramp up the utilization of
telemedicine. This presents an additional learning curve for
implementation and interface with our community partners.
Investigating strategies and infrastructure requirements to
offer virtual training and real time consultation to
non-specialty providers can expand the number of providers
that can be trained and ultimately grow the pool of providers
who can deliver knowledgeable and appropriate care for
SCD across the state.
IMPLICATIONS FOR PUBLIC HEALTH
This project is an example of finding ways to utilize existing
resources in areas that are poorly resourced, looking beyond
the deficits in underserved and under-resourced areas and
finding ways to leverage and build on the resources that are
in place. The SCFG Access to Care Project takes an
innovative approach working with a diverse group of
stakeholders to plan, implement, and evaluate the project.
SCFG engaged with community organizations during both
the planning and implementation stages of the project.
Community stakeholder meetings included representatives
of community organizations, health care providers, and
individuals living with sickle cell disease. Stakeholders
identified community needs, strengths, and resources and
identified potential community partners. State and local
level policy makers provided input on the areas of the state
in need of services; developed state policies; and made
resources available to implement project activities. The
project collaborated with public, private, and faith-based
community health centers to develop protocols and
processes needed to provide hematology care to individuals
with SCD in their areas and to increase access to primary
and other sub-specialty care (behavioral health, OB/GYN).
Physicians and consultants in private practice plan the
delivery of medical services and collaborate with academic
institutions to plan and deliver training for health care
providers.
This project engaged partners across disciplines (including
individuals living with SCD); encouraged and granted local
ownership of project activities; and demonstrated flexibility
in mid-course operations corrections. This strategy resulted
in increased access to care in underserved areas of the state
and can easily be replicated in other communities and
disease sectors.
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APPENDIX
Provider Training Toolkit Contents
Information
● Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease: A Pocket Guide for the Clinician, 2014,
American Society of Hematology, www.hematology.org
● Management of Complications of Sickle Cell Disease: A Pocket Guide for the Clinician, 2014, American Society of
Hematology, www.hematology.org
● Health Maintenance and Management of Chronic Complications of Sickle Cell Disease: A Pocket Guide for the
Clinician, 2014, American Society of Hematology, www.hematology.org
● Red Blood Cell Transfusion: A Pocket Guide for the Clinician, 2016, American Society of Hematology,
www.hematology.org
● Emergency Management of Sickle Cell Disease, National Heart, Lung and Blood Institute algorithm for the management
of acute pain crises
● Hydroxyurea (patient brochure), Sickle Cell Disease Association of America/Sickle Cell Foundation of Georgia
● Living Well with Sickle Cell: Community Health Services for People with Sickle Cell, Georgia Community
Connections, Sickle Cell Foundation of Georgia
● Sickle Cell Disease and Family Planning, Sickle Cell Foundation of Georgia
Additional Training Opportunities
● Fact Sheet and Enrollment Information – The Sickle Cell Disease (SCD) Training and Mentoring Program (STAMP): A
Pilot Program for Primary Care Providers, U.S. Department of Health and Human Services, Office of Minority Health
● Fact Sheet and Schedule – Improve Sickle Cell Care and Outcomes with Project ECHO, Atrium Health, Levine Cancer
Institute
● Training Description and Access Information – Reducing Complications of Therapeutic Blood Transfusion for Sickle
Cell Disease, Georgia Health Policy Center, Georgia State University
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